Miura Global Management LLC bought a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 25,000 shares of the medical research company's stock, valued at approximately $3,958,000. Natera accounts for 4.3% of Miura Global Management LLC's holdings, making the stock its 6th biggest holding.
Several other large investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Natera by 7.7% during the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock valued at $1,949,697,000 after buying an additional 879,463 shares during the period. Price T Rowe Associates Inc. MD grew its position in Natera by 134.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock valued at $1,067,327,000 after buying an additional 3,871,862 shares during the period. JPMorgan Chase & Co. grew its position in Natera by 43.7% during the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after buying an additional 2,036,396 shares during the period. Wellington Management Group LLP lifted its holdings in Natera by 15.7% during the fourth quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock valued at $512,898,000 after purchasing an additional 439,778 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Natera by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock valued at $355,809,000 after purchasing an additional 142,201 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.
Natera Price Performance
NTRA traded up $3.19 during trading hours on Friday, hitting $152.59. The company's stock had a trading volume of 911,043 shares, compared to its average volume of 1,386,529. The business's 50-day moving average price is $148.71 and its 200-day moving average price is $156.51. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00. The stock has a market cap of $20.63 billion, a price-to-earnings ratio of -86.70 and a beta of 1.79. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.
Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. During the same quarter in the previous year, the business posted ($0.56) earnings per share. Natera's quarterly revenue was up 36.5% on a year-over-year basis. Sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
NTRA has been the topic of several analyst reports. BTIG Research reaffirmed a "buy" rating on shares of Natera in a report on Friday, February 28th. Morgan Stanley lifted their price target on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Royal Bank of Canada initiated coverage on shares of Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price target on the stock. Piper Sandler lifted their price target on shares of Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Thursday. Finally, Barclays lifted their price target on shares of Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a report on Friday, May 9th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $182.12.
View Our Latest Analysis on Natera
Insider Buying and Selling at Natera
In other Natera news, insider Solomon Moshkevich sold 6,000 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total transaction of $859,740.00. Following the transaction, the insider now owns 143,768 shares in the company, valued at $20,600,516.72. The trade was a 4.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider John Fesko sold 343 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $145.55, for a total transaction of $49,923.65. Following the transaction, the insider now owns 156,946 shares in the company, valued at $22,843,490.30. This trade represents a 0.22% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 152,436 shares of company stock worth $22,019,079 over the last quarter. Insiders own 7.60% of the company's stock.
About Natera
(
Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Further Reading
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
